Navigation Links
Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Date:1/7/2008

Ortho-McNeil to Continue Investigation of GDIR Agonists Under its

Partnership with Arena

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that initial clinical study results for APD668, an oral drug candidate discovered by Arena and being investigated for the treatment of type 2 diabetes under a partnership with Ortho-McNeil Pharmaceutical, Inc., suggest that Glucose-Dependent Insulinotropic Receptors, or GDIRs, may improve glucose control in patients with type 2 diabetes.

Ortho-McNeil's initial clinical studies evaluated healthy volunteers and patients with type 2 diabetes in randomized, double-blind, placebo-controlled trials evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple (14 day) escalating doses of APD668. Based on the data from those studies, Ortho-McNeil has decided to put APD668 on hold and has advanced a potentially more potent Arena discovered GDIR agonist into preclinical development.

"We are encouraged by the clinical study results supporting GDIR agonists as effective modulators of glucose homeostasis in patients with type 2 diabetes, and we look forward to the results of Ortho-McNeil advancing another of Arena's GDIR compounds into development," stated Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer.

About the Glucose-Dependent Insulinotropic Receptor (GDIR)

The GDIR is an orphan G protein-coupled receptor, or GPCR, discovered by Arena. It is expressed in beta cells, the cells in the pancreas responsible for producing insulin in response to increases in blood glucose. Stimulation of the GDIR is intended to more efficiently
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
2. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
3. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
4. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
5. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
6. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
7. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...HOUSTON, Nov. 20 Cyberon...n Moore, President and Chief Executive Officer, an...nt at the 21st Annual Piper Jaffray Health Care Co...9 at 12:00 PM EST. The conference session and web...be presented. Piper Jaffray will host a webcast o...
(Date:11/20/2009)...NKLIN LAKES, N.J., Nov. 20 /PRNewswire-FirstCall/ ... ) today announced the completion of its acquisiti... company that develops and manufactures molecular ...In May 2009, BD and HandyLab announced an exclusiv...lecular assays on the HandyLab Jaguar(TM) platform...
(Date:11/20/2009)...RINCETON, N.J., Nov. 20 ...nix or the Company), formerly known as DOR BioPhar...unced today that it has formed a consortium to dev...and other rapidly acting vaccines. Soligenix recei...te of Allergy and Infectious Diseases (NIAID), a d...
Breaking Medicine Technology:Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6LaserSculpt Inc Launches LaserSculpt Infomercial 55539 1Joint Commission Alert 3A Effective Leadership Critical to Preventing Medical Errors 55534 1Joint Commission Alert 3A Effective Leadership Critical to Preventing Medical Errors 55534 2Joint Commission Alert 3A Effective Leadership Critical to Preventing Medical Errors 55534 3CenterWatch Celebrates 15 Year Milestone as Leading Information Provider for the Clinical Trials Industry 55529 1CenterWatch Celebrates 15 Year Milestone as Leading Information Provider for the Clinical Trials Industry 55529 2
... of mature dendritic cells with tumor lysate,trigg...SBURG, Md., and YOKOHAMA, Japan, June 22, 2007,/PR...nnounce a,joint poster presentation at the 13th An...ular Therapy. The meeting is being,held June 24-27... entitled "Electroloading of mature dendritic,cell...
...--(BUSINESS WIRE)--Jun 21, 2007 - Advanced Cell,Te...uced a human,embryonic stem cell (hESC) line witho...assachusetts. This development was announced by,Ro...Development of,Advanced Cell Technology (ACT) on T...ional Society for Stem Cell Research (ISSCR),in Ca...
Other Medicine Technology:MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 2MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 3Advanced Cell Technology Develops First Human Embryonic Stem Cell,Line without Destroying an Embryo 2Advanced Cell Technology Develops First Human Embryonic Stem Cell,Line without Destroying an Embryo 3
(Date:11/20/2009)...Nov. 20 /PRNewswire-FirstCall/ - NUCRYST Pharmaceu...g of Shareholders will be held on Monday, December...er approval of two special resolutions. The first ... sale of all or substantially all of the assets of...in the asset purchase agreement dated November 10,...
(Date:11/20/2009)..., Nov. 20 Rates of infec...ked in late October, but the pandemic flu virus co... age groups, including the elderly, according to a...E: DGX ), the world,s leading provider of diagno...its most recent Quest Diagnostics Health Trends(TM...
(Date:11/20/2009)...0 The following is a st...e Nevada Health Care Association: ,, "The Nevad...ks Senate Majority Leader Harry Reid for his leade...r goal of protecting every Nevada seniors, ongoing...ng the strength and viability of our state,s vital...
(Date:11/20/2009)...ember 20, 2009Emergency medical service (EMS) prov...,000 cardiac arrests each year. Only 5 to 10 perc...ve. Better quality cardiopulmonary resuscitation ... associated with better patient outcome. The Resu... clinical research network to study prehospital tr...
(Date:11/20/2009)...igh and is expected to continue, CDC says, , ...reas of the United States are seeing declines in H...said Friday, and while the disease remains widespr...eported last week. , "We are beginning to see s...try, but there is still a lot of influenza everywh...
Breaking Medicine News(10 mins):Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3
...C., Jan. 9 Palmetto GBA, a leading provider of te...l government, has been selected by the federal Cen... process and pay all fee-for-service Medicare clai...ded Palmetto GBA a contract with a base period of ...
...O, Mich., Jan. 9 Stryker Corporation,(NYSE: SYK...ion for the fourth,quarter of 2008, representing a...r the fourth quarter of 2007, and were $6,718 mill...onstant currency basis,net sales increased 7.7% fo...
...OGA, Tenn., Jan. 9 Shared Health, one of the,nati...hanges, announced today,the appointment of Adnane ...formation officer. , Khalil will focus on buil...re than 15 years experience in creating, integrati...
...es & Martinis at Dashing Diva , , NEW YORK, J...a baby now, but they should be seeking the answers...,ll be able to have a baby when they are ready. Th...ght to do everything possible to keep from getting...
... Biocoat, Inc., Horsham, PA announced... been created and linked to the company,s website ...turers and designers can go to find the latest dev...9 -- Biocoat, Inc., Horsham, PA announced that a ...
...n. 8 New York City Mayor Michael R. Bloomberg dec...and presented a proclamation to Ilchi Lee, preside...tion) and developer of Brain Education, a revoluti...ng the power of individuals to change themselves a...
Other Medicine News:Health News:CMS Selects Palmetto GBA to Administer Medicare Program in Four States 2Health News:Stryker Updates Expected 2008 Results and Provides 2009 Outlook 2Health News:Stryker Updates Expected 2008 Results and Provides 2009 Outlook 3Health News:Stryker Updates Expected 2008 Results and Provides 2009 Outlook 4Health News:Shared Health(R) Names Adnane Khalil as Chief Information Officer 2Health News:Free Early Education Program to Lower Infertility Rates 2Health News:Free Early Education Program to Lower Infertility Rates 3Health News:Blog Launched to Discuss Developments in Hydrophilic Coatings for Medical Devices 2Health News:NYC Mayor Michael R. Bloomberg Declares January 8th 'IBREA Brain Education Day' 2
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: